share_log

Standard BioTools Reaffirms Guidance

Benzinga ·  May 8 17:39

Outlook for 2024

For fiscal year 2024, the Company reaffirmed full year revenue guidance, which is expected to be in the range of $200 million to $205 million.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment